Adagene Showcases ADG126 + Keytruda Data in Late-Line MSS-CRC Presentation
Adagene showcased ADG126 plus Keytruda combination data in late-line microsatellite-stable colorectal cancer, highlighting safety, tolerability and preliminary disease control metrics at the Oppenheimer Healthcare Conference. Presenters detailed study design, patient eligibility criteria and timing for the next data update.
1. Study Design and Objectives
At the Oppenheimer Healthcare Conference, Adagene outlined its Phase 1 study design for ADG126 in combination with Keytruda targeting late-line microsatellite-stable colorectal cancer. The presentation covered dosing cohorts, patient eligibility criteria, and primary safety and tolerability endpoints guiding dose escalation.
2. Preliminary Data and Development Path
Adagene highlighted preliminary disease control metrics observed in the initial cohorts, noting acceptable safety and tolerability in combination with Keytruda. Management discussed enrollment progress, anticipated data readout timelines, and plans for advancing to expansion cohorts pending full safety evaluation.